Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models
Open Access
- 16 June 2021
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (6) , 793-802
Abstract
Treatment of castration-resistant prostate cancer remains a challenging clinical problem. Despite the promising effects of immunotherapy in other solid cancers, prostate cancer has remained largely unresponsive. Oncolytic viruses represent a promising therapeutic avenue, as oncolytic virus treatment combines tumour cell lysis with activation of the immune system and mounting of effective anti-tumour responses. Mammalian Orthoreoviruses are non-pathogenic human viruses with a preference of lytic replication in human tumour cells. In this study, we evaluated the oncolytic efficacy of the bioselected oncolytic reovirus mutant jin-3 in multiple human prostate cancer models. The jin-3 reovirus displayed efficient infection, replication, and anti-cancer responses in 2D and 3D prostate cancer models, as well as in ex vivo cultured human tumour slices. In addition, the jin-3 reovirus markedly reduced the viability and growth of human cancer cell lines and patient-derived xenografts. The infection induced the expression of mediators of immunogenic cell death, interferon-stimulated genes, and inflammatory cytokines. Taken together, our data demonstrate that the reovirus mutant jin-3 displays tumour tropism, and induces potent oncolytic and immunomodulatory responses in human prostate cancer models. Therefore, jin-3 reovirus represents an attractive candidate for further development as oncolytic agent for treatment of patients with aggressive localised or advanced prostate cancer.Keywords
This publication has 35 references indexed in Scilit:
- Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-APLOS ONE, 2012
- Reovirus as a Viable Therapeutic Option for the Treatment of Multiple MyelomaClinical Cancer Research, 2012
- Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancerBMC Cancer, 2011
- Oncolytic Virus-initiated Protective Immunity Against Prostate CancerMolecular Therapy, 2011
- REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced CancerClinical Cancer Research, 2010
- Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell ModelsPLOS ONE, 2010
- High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate CancerCancer Research, 2010
- Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological TherapeuticCancer Research, 2010
- Reciprocal Human Dendritic Cell–Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic ReovirusThe Journal of Immunology, 2009
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced CancerClinical Cancer Research, 2008